Literature DB >> 18448568

The European consensus on ulcerative colitis: new horizons?

Eduard F Stange1, Simon P L Travis.   

Abstract

Entities:  

Mesh：

Year:  2008        PMID： 18448568     DOI： 10.1136/gut.2007.146761

Source DB:  PubMed          Journal:  Gut        ISSN： 0017-5749            Impact factor:   23.059


× No keyword cloud information.
  6 in total

Review 1.  Top-down therapy for IBD: rationale and requisite evidence.

Authors:  Geert R D'Haens
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2010-02       Impact factor: 46.802

Review 2.  Inflammatory bowel disease in the elderly.

Authors:  Syed Wasif Hussain; Darrell S Pardi
Journal:  Drugs Aging       Date:  2010-08-01       Impact factor: 3.923

3.  Combining aneuploidy and dysplasia for colitis' cancer risk assessment outperforms current surveillance efficiency: a meta-analysis.

Authors:  Rüdiger Meyer; Sandra Freitag-Wolf; Silke Blindow; Jürgen Büning; Jens K Habermann
Journal:  Int J Colorectal Dis       Date:  2016-10-20       Impact factor: 2.571

4.  Colorectal neoplasia in IBD--a single-center analysis of patients undergoing proctocolectomy.

Authors:  Rüdiger Meyer; Tilman Laubert; Martin Sommer; Claudia Benecke; Hendrik Lehnert; Klaus Fellermann; Hans-Peter Bruch; Tobias Keck; Christoph Thorns; Jens K Habermann; Jürgen Büning
Journal:  Int J Colorectal Dis       Date:  2015-04-26       Impact factor: 2.571

5.  Synergic modulation of the inflammatory state of macrophages utilizing anti-oxidant and phosphatidylserine-containing polymer-lipid hybrid nanoparticles.

Authors:  Md Zahangir Hosain; Kazuki Yuzuriha; Masafumi Takeo; Akihiro Kishimura; Yoshihiko Murakami; Takeshi Mori; Yoshiki Katayama
Journal:  Medchemcomm       Date:  2017-06-02       Impact factor: 3.597

Review 6.  Current and emerging biologics for ulcerative colitis.

Authors:  Sung Chul Park; Yoon Tae Jeen
Journal:  Gut Liver       Date:  2015-01       Impact factor: 4.519
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.